Brought to you by 
Trek Therapeutics gets license to Theravance's HCV candidate
01 Feb 2023
Executive Summary
Theravance Biopharma Inc. licensed Trek Therapeutics PBC (TrekTx) exclusive worldwide rights to develop, manufacture, and commercialize TD6450 in combination hepatitis C products.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trek Therapeutics gets license to Theravance's HCV candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice